<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">26957112</PMID>
      <DateCompleted>
        <Year>2016</Year>
        <Month>10</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>19</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1756-8722</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>9</Volume>
            <PubDate>
              <Year>2016</Year>
              <Month>Mar</Month>
              <Day>09</Day>
            </PubDate>
          </JournalIssue>
          <Title>Journal of hematology &amp; oncology</Title>
          <ISOAbbreviation>J Hematol Oncol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor.</ArticleTitle>
        <Pagination>
          <StartPage>21</StartPage>
          <MedlinePgn>21</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">21</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13045-016-0250-9</ELocationID>
        <Abstract>
          <AbstractText>More and more targeted agents become available for B cell malignancies with increasing precision and potency. The first-in-class Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib, has been in clinical use for the treatment of chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. More selective BTK inhibitors (ACP-196, ONO/GS-4059, BGB-3111, CC-292) are being explored. Acalabrutinib (ACP-196) is a novel irreversible second-generation BTK inhibitor that was shown to be more potent and selective than ibrutinib. This review summarized the preclinical research and clinical data of acalabrutinib.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wu</LastName>
            <ForeName>Jingjing</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Mingzhi</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Delong</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Oncology, The first Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Delong_liu@nymc.edu.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2016</Year>
          <Month>03</Month>
          <Day>09</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Hematol Oncol</MedlineTA>
        <NlmUniqueID>101468937</NlmUniqueID>
        <ISSNLinking>1756-8722</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D001549">Benzamides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D011719">Pyrazines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D011505">Protein-Tyrosine Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D000077329">Agammaglobulinaemia Tyrosine Kinase</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="C000625949">BTK protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>I42748ELQW</RegistryNumber>
          <NameOfSubstance UI="C000604908">acalabrutinib</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000077329" MajorTopicYN="N">Agammaglobulinaemia Tyrosine Kinase</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D001549" MajorTopicYN="N">Benzamides</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002986" MajorTopicYN="N">Clinical Trials as Topic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000201" MajorTopicYN="N">enzymology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011505" MajorTopicYN="N">Protein-Tyrosine Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="Y">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D011719" MajorTopicYN="N">Pyrazines</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D023041" MajorTopicYN="N">Xenograft Model Antitumor Assays</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2016</Year>
          <Month>2</Month>
          <Day>23</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>1</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2016</Year>
          <Month>3</Month>
          <Day>10</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2016</Year>
          <Month>10</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">26957112</ArticleId>
        <ArticleId IdType="pmc">PMC4784459</ArticleId>
        <ArticleId IdType="doi">10.1186/s13045-016-0250-9</ArticleId>
        <ArticleId IdType="pii">10.1186/s13045-016-0250-9</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al.  Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370(12):1101–10. doi: 10.1056/NEJMoa1313984.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1313984</ArticleId>
            <ArticleId IdType="pubmed">24401022</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fan G, Wang Z, Hao M, Li J. Bispecific antibodies and their applications. J Hematol Oncol. 2015;8(1):1–14. doi: 10.1186/s13045-014-0099-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-014-0099-8</ArticleId>
            <ArticleId IdType="pubmed">0</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I, et al.  A tetravalent bispecific TandAb (CD19/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs. 2015;7(3):584–604. doi: 10.1080/19420862.2015.1029216.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/19420862.2015.1029216</ArticleId>
            <ArticleId IdType="pmc">PMC4622993</ArticleId>
            <ArticleId IdType="pubmed">25875246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Suresh T, Lee L, Joshi J, Barta S. New antibody approaches to lymphoma therapy. J Hematol Oncol. 2014;7(1):58. doi: 10.1186/s13045-014-0058-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-014-0058-4</ArticleId>
            <ArticleId IdType="pmc">PMC4172963</ArticleId>
            <ArticleId IdType="pubmed">25355407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thomas X. Blinatumomab: a new era of treatment for adult ALL? Lancet Oncol. 2014;16(1):6–7. doi: 10.1016/S1470-2045(14)71183-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1470-2045(14)71183-0</ArticleId>
            <ArticleId IdType="pubmed">25524799</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Fu J, Zhang M, Liu D. AFM13: a first-in-class tetravalent bispecific anti-CD30/CD16A antibody for NK cell-mediated immunotherapy. J Hematol Oncol. 2015;8:96. doi: 10.1186/s13045-015-0188-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-015-0188-3</ArticleId>
            <ArticleId IdType="pmc">PMC4522136</ArticleId>
            <ArticleId IdType="pubmed">26231785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu J, Fu J, Zhang M, Liu D. Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia. J Hematol Oncol. 2015;8(1):104. doi: 10.1186/s13045-015-0195-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-015-0195-4</ArticleId>
            <ArticleId IdType="pmc">PMC4558758</ArticleId>
            <ArticleId IdType="pubmed">26337639</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cang S, Iragavarapu C, Savooji J, Song Y, Liu D. ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development. J Hematol Oncol. 2015;8(1):129. doi: 10.1186/s13045-015-0224-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-015-0224-3</ArticleId>
            <ArticleId IdType="pmc">PMC4654800</ArticleId>
            <ArticleId IdType="pubmed">26589495</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al.  Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311–22. doi: 10.1056/NEJMoa1513257.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1513257</ArticleId>
            <ArticleId IdType="pmc">PMC7107002</ArticleId>
            <ArticleId IdType="pubmed">26639348</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rai K. Therapeutic potential of new B cell-targeted agents in the treatment of elderly and unfit patients with chronic lymphocytic leukemia. J Hematol Oncol. 2015;8(1):85. doi: 10.1186/s13045-015-0165-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-015-0165-x</ArticleId>
            <ArticleId IdType="pmc">PMC4522086</ArticleId>
            <ArticleId IdType="pubmed">26170206</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Novero A, Ravella PM, Chen Y, Dous G, Liu D. Ibrutinib for B cell malignancies. Experimental Hematology &amp; Oncology. 2014;3(1):1–7. doi: 10.1186/2162-3619-3-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/2162-3619-3-4</ArticleId>
            <ArticleId IdType="pmc">PMC3913970</ArticleId>
            <ArticleId IdType="pubmed">24472371</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;373(6):584–6. doi: 10.1056/NEJMc1506192.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc1506192</ArticleId>
            <ArticleId IdType="pubmed">26244327</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, et al.  Ibrutinib in previously treated Waldenstrom’s macroglobulinemia. N Engl J Med. 2015;372(15):1430–40. doi: 10.1056/NEJMoa1501548.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1501548</ArticleId>
            <ArticleId IdType="pubmed">25853747</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao Y, Yang G, Hunter ZR, Liu X, Xu L, Chen J, et al.  The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells. Br J Haematol. 2015;170(1):134–8. doi: 10.1111/bjh.13278.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/bjh.13278</ArticleId>
            <ArticleId IdType="pubmed">25582069</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32–42. doi: 10.1056/NEJMoa1215637.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1215637</ArticleId>
            <ArticleId IdType="pmc">PMC3772525</ArticleId>
            <ArticleId IdType="pubmed">23782158</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16. doi: 10.1056/NEJMoa1306220.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1306220</ArticleId>
            <ArticleId IdType="pmc">PMC4513941</ArticleId>
            <ArticleId IdType="pubmed">23782157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Brown JR, Barrientos JC, Barr PM, Flinn IW, Burger JA, Tran A, et al.  The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. Blood. 2015;125(19):2915–22. doi: 10.1182/blood-2014-09-585869.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2014-09-585869</ArticleId>
            <ArticleId IdType="pmc">PMC4424415</ArticleId>
            <ArticleId IdType="pubmed">25755291</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Burger JA, Tedeschi A, Barr PM, Robak T, Owen C, Ghia P, et al.  Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425–37. doi: 10.1056/NEJMoa1509388.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509388</ArticleId>
            <ArticleId IdType="pmc">PMC4722809</ArticleId>
            <ArticleId IdType="pubmed">26639149</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, et al.  Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage in chronic lymphocytic leukemia (CLL) patients. Cancer Res. 2015;75(15 Supplement):2596. doi: 10.1158/1538-7445.AM2015-2596.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2015-2596</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vidal-Crespo A, Rodríguez V, Matas-Céspedes A, Campos E, López-Guillermo A, Roué G, et al.  Abstract 1757: the novel BTK inhibitor CC-292 exerts in vitro and in vivo antitumor activity, interferes with adhesion, cell migration, and synergizes with lenalidomide in MCL models. Cancer Res. 2014;74(19 Supplement):1757. doi: 10.1158/1538-7445.AM2014-1757.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2014-1757</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Na L, Zhijian S, Ye L, Mingming G, Yilu Z, Dongping Z, et al.  Abstract 2597: BGB-3111 is a novel and highly selective Bruton’s tyrosine kinase (BTK) inhibitor. Cancer Res. 2015;75:2597. doi: 10.1158/1538-7445.AM2015-2597.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2015-2597</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tam C, Grigg AP, Opat S, Ku M, Gilbertson M, Anderson MA, et al.  The BTK inhibitor, Bgb-3111, is safe, tolerable, and highly active in patients with relapsed/refractory B-cell malignancies: initial report of a phase 1 first-in-human trial. Blood. 2015;126(23):832.</Citation>
        </Reference>
        <Reference>
          <Citation>Walter HS, Rule SA, Dyer MJS, Karlin L, Jones C, Cazin B, et al.  A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. Blood. 2016;127(4):411–9. doi: 10.1182/blood-2015-08-664086.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1182/blood-2015-08-664086</ArticleId>
            <ArticleId IdType="pmc">PMC4731845</ArticleId>
            <ArticleId IdType="pubmed">26542378</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Byrd JC, Harrington B, O'Brien S, Jones JA, Schuh A, Devereux S, et al.  Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32. doi: 10.1056/NEJMoa1509981.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1509981</ArticleId>
            <ArticleId IdType="pmc">PMC4862586</ArticleId>
            <ArticleId IdType="pubmed">26641137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gardner* HL, Harrington* BK, Izumi R, Hamdy A, Kaptein A, Lith BV, et al.  Abstract 1744: ACP-196: a second generation Btk inhibitor demonstrates biologic activity in a canine model of B-cell non-Hodgkin lymphoma. Cancer Res. 2014;74(19 Supplement):1744. doi: 10.1158/1538-7445.AM2014-1744.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2014-1744</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Harrington BK, Gulrajani M, Covey T, Kaptein A, Van Lith B, Izumi R, et al.  ACP-196 is a second generation inhibitor of Bruton tyrosine kinase (BTK) with enhanced target specificity. Blood. 2015;126(23):2908.</Citation>
        </Reference>
        <Reference>
          <Citation>Lannutti BJ, Gulrajani M, Krantz F, Bibikova E, Covey T, Jessen K, et al.  Abstract 408: ACP-196, an orally bioavailable covalent selective inhibitor of Btk, modulates the innate tumor microenvironment, exhibits antitumor efficacy and enhances gemcitabine activity in pancreatic cancer. Cancer Res. 2015;75(15 Supplement):408. doi: 10.1158/1538-7445.AM2015-408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2015-408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Niemann CU, Montraveta A, Herman SEM, Ingallinera T, Barf T, Colomer D, et al.  Abstract 2624: the novel Bruton’s tyrosine kinase inhibitor ACP-196 shows in vivo efficacy against human chronic lymphocytic leukemia cells xenografted to the NSG mouse model. Cancer Res. 2014;74(19 Supplement):2624. doi: 10.1158/1538-7445.AM2014-2624.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1538-7445.AM2014-2624</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Herman SEM, Montraveta A, Niemann CU, Mora-Jensen H, Gulrajani M, Krantz F, et al.  The Bruton tyrosine kinase (BTK) inhibitor ACP-196 demonstrates clinical activity in two mouse models of chronic lymphocytic leukemia. Blood. 2015;126(23):2920.</Citation>
        </Reference>
        <Reference>
          <Citation>Herman SE, Sun X, McAuley EM, Hsieh MM, Pittaluga S, Raffeld M, et al.  Modeling tumor-host interactions of chronic lymphocytic leukemia in xenografted mice to study tumor biology and evaluate targeted therapy. Leukemia. 2013;27(12):2311–21. doi: 10.1038/leu.2013.131.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/leu.2013.131</ArticleId>
            <ArticleId IdType="pmc">PMC4126654</ArticleId>
            <ArticleId IdType="pubmed">23619564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rai KR, Barrientos JC. Movement toward optimization of CLL therapy. N Engl J Med. 2014;370(12):1160–2. doi: 10.1056/NEJMe1400599.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMe1400599</ArticleId>
            <ArticleId IdType="pubmed">24645950</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang Q, Modi P, Newcomb T, Queva C, Gandhi V. Idelalisib: first-in-class PI3K delta inhibitor for the treatment of chronic lymphocytic leukemia, small lymphocytic leukemia, and follicular lymphoma. Clin Cancer Res. 2015;21(7):1537–42. doi: 10.1158/1078-0432.CCR-14-2034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1158/1078-0432.CCR-14-2034</ArticleId>
            <ArticleId IdType="pmc">PMC4523214</ArticleId>
            <ArticleId IdType="pubmed">25670221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Iragavarapu C, Mustafa M, Akinleye A, Furqan M, Mittal V, Cang S, et al.  Novel ALK inhibitors in clinical use and development. J Hematol Oncol. 2015;8(1):17. doi: 10.1186/s13045-015-0122-8.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-015-0122-8</ArticleId>
            <ArticleId IdType="pmc">PMC4349797</ArticleId>
            <ArticleId IdType="pubmed">25888090</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parikh K, Cang S, Sekhri A, Liu D. Selective inhibitors of nuclear export (SINE)—a novel class of anti-cancer agents. J Hematol Oncol. 2014;7(1):78. doi: 10.1186/s13045-014-0078-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s13045-014-0078-0</ArticleId>
            <ArticleId IdType="pmc">PMC4200201</ArticleId>
            <ArticleId IdType="pubmed">25316614</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Das A, Wei G, Parikh K, Liu D. Selective inhibitors of nuclear export (SINE) in hematological malignancies. Exp Hematol Oncol. 2015;4:7. doi: 10.1186/s40164-015-0002-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s40164-015-0002-5</ArticleId>
            <ArticleId IdType="pmc">PMC4350974</ArticleId>
            <ArticleId IdType="pubmed">25745591</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al.  ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202–8. doi: 10.1038/nm.3048.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nm.3048</ArticleId>
            <ArticleId IdType="pubmed">23291630</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao X, Rajasekaran N, Reusch U, Weichel M, Ellwanger K, Marschner J-P, et al.  In vitro and in vivo characterization of CD19/CD3 Tandab AFM11 and CD19/CD16A Tandab AFM12 targeting NHL. Blood. 2015;126(23):2763.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
